According to a recently published report by Brisk Insights, the Global Chronic Idiopathic Constipation (CIC) Drug Market is expected to grow at the CAGR of 6.4% during 2017-2025. The global chronic idiopathic constipation (CIC) drug market is segmented on the basis of drug, prescription and geography. The report on global chronic idiopathic constipation (CIC) drug market (by drug, prescription and geography) provides a detailed overview and predictive analysis of the market.
Full report available on Chronic Idiopathic Constipation (CIC) Drug Market: Global Industry Size, Growth, Share and Forecast to 2025 report at http://www.briskinsights.com/report/chronic-idiopathic-constipation-cic-drugs-market
The global chronic idiopathic constipation (CIC) drugs market is significantly growing due to the growing prevalence of global chronic idiopathic constipation. It is estimated that more than 15% of adult population in United States and Europe is affected with chronic idiopathic constipation. Rising number of geriatric population, effective drugs in pipeline and unhealthy dietary habits would drive the growth of CIC drugs market worldwide. Currently, medication such as Lubiprostone, Cisapride, Tegaserod, Prucalopride, Linaclotide and Naloxone are most widely used in market. Plecanatide is newly approved by US-FDA and it is expected to create further growth opportunities in the market. It is observed that, in the base year 2016, Lubiprostone is most widely used in market, due to its proven efficiency and established safety profile. It is estimated that OTC drug market will continue grow at fastest CAGR during forecast period because constipation is generally not considered as disease and thus people are less likely to visit doctors to get prescription for constipation. Currently, North America is dominating CIC drugs market, higher number of geriatric population driving the growth of CIC market in North America. Significant unmet needs and increasing healthcare awareness would create significant opportunity for the market players in Asia Pacific.
Request Sample: http://www.briskinsights.com/sample-request/585
Scope of the report
1. Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Drug Type, 2015–2025 ($ Millon)
1.4. Pipeline Drug Analysis: Elobixibat
1.5. Pipeline Drug Analysis: Relenopride
2. Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Prescription Type, 2015–2025 ($ Millon)
2.1. Prescription Drugs
2.2. Over the Counter Drugs
3. Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Geography, 2015-2025 ($ Millon)
3.1. North America
3.2.4. Rest of Europe
3.3. Asia Pacific
3.3.3. Rest of Asia Pacific
3.4. Latin America (LATAM)
3.4.3. Rest of Latin America
3.5. Middle East and Africa (MEA)
3.5.2. Rest of Middle East and Africa
4. Company Profiles
4.2. Bayer AG
4.3. Chugai Pharmaceutical
4.4. Ferring International Center S.A.
4.6. Ironwood Pharmaceuticals Inc.
4.8. Progenics pharmaceuticals Inc.
4.9. Roche Holding AG
4.10. Salix Pharmaceuticals Ltd.
4.12. Sucampo Pharmaceuticals Inc.
4.13. Synergy Pharmaceuticals
4.14. Other Major Players
About Us :
Brisk Insights is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to aid businesses identify market opportunities optimize strategies.
Working in a highly dynamic and multi-dimensional business makes decision making complex. Effective business decisions are a result of the synthesis of market information. Our Research and data analysis is an efficient and cost-effective way of providing robust market analysis and can yield highly valuable intelligence relating to consumers, competitors and markets.
Contact Us :
109 Vernon House
Phone : +448081890034 (UK)
Website : http://www.briskinsights.com/